Shares of BioMimetic Therapeutics are primed to pop Tuesday after the company said it furnished regulators with the information and test data they requested earlier this year. After-hours investors bid BioMimetic (Ticker: BMTI) up 11 percent to $3.11.

“[W]e believe this information strongly supports the robustness of the findings and the PMA approval of Augment. Additionally, the conclusion we have reached based on the data, that Augment is safe and effective, is consistent with the recommendation of the overwhelming majority of practicing physicians on the FDA’s Advisory Panel and the unanimous votes by the orthopedic foot and ankle specialists on the Advisory Panel.”